During the business breakfast, Vikram Punia discussed investment opportunities for the production of urgently needed medical devices in the country. At the end of the event, it was decided to continue deliberating on the matter.
INNOPROM, Russia's largest industrial exhibition, takes place in Yekaterinburg from July 8 to 11, showcasing sectors such as engineering, energy, metallurgy, industrial automation, IT, pharmaceuticals, healthcare, and others. In 2024, the event's partner country is the United Arab Emirates (UAE).
Oleg Astafurov, Vice President for Government Relations of the Pharmasyntez Group, spoke as an expert in the session Developing Russia's Bioeconomy: Identifying Industrial Priorities, which was moderated by Vasily Osmakov, First Deputy Minister of Industry and Trade of the Russian Federation.
Oleg Astafurov is confident that the domestic bioeconomy program should include amendments to Federal Law No. 44 that prioritize domestic innovative medicines in public procurement.
“Certainly, the government is committed to technological sovereignty and ensuring that the healthcare system has access to effective, innovative medicines, especially in the face of sanctions from unfriendly countries. However, a dedicated program to support Russia’s bioeconomy is required, including state funding for preclinical and clinical trials.”
On July 9, the keynote strategic session titled Technological Partnership: A Focus for International Business featured Mikhail Mishustin, Prime Minister of Russia, and Dr. Thani Al Zeyoudi, UAE Minister of State for Foreign Trade, as well as officials from other countries.
By September 1, 2024, six new national projects, including New Health Preservation Technologies, will be presented to the profile Presidential Council. The national project, set to begin in 2025, will consolidate and coordinate all types of medical research and development efforts, focusing on breakthrough technologies such as high-technology medicinal products, innovative medical devices, new cellular products, biomedical technologies, radiopharmaceuticals, and the development of artificial intelligence in healthcare.
“We aim to increase domestic production of vital and essential medications to 90%,” Mikhail Mishustin stated during the national project's strategic session.
The Pharmasyntez Group's most relevant drugs, as identified by the Ministry of Industry and Trade, were on display at the ministry's exhibition booth. This year's INNOPROM placed a strong emphasis on the pharmaceutical sector. Anton Alikhanov stated that industry plays a critical role in advancing industrial collaboration.